menu
    • menu

    Company profile for Julphar Gulf Pharmaceutical Industries

    NEW Drugs in Dev: 3
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Julphar is a true reflection of Ras Al Khaimah’s significant development. Established in 1980 under the guidance of H.H Sheikh Saqr Bin Mohammed Al Qasimi, we have established ourselves as a leader in production and distribution of pharmaceutical products. Our goal is to create high-quality medicines whilst maintaining a competitive cost. We achieve this through a network of twelve world-class manufacturing plants (with f...
    Julphar is a true reflection of Ras Al Khaimah’s significant development. Established in 1980 under the guidance of H.H Sheikh Saqr Bin Mohammed Al Qasimi, we have established ourselves as a leader in production and distribution of pharmaceutical products. Our goal is to create high-quality medicines whilst maintaining a competitive cost. We achieve this through a network of twelve world-class manufacturing plants (with further expansion planned) and a reliable logistics network which covers five continents.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Julphar Gulf Pharmaceutical Industriessaudiarabiapng-1555324364png-1605701218 Flag
    Country
    Country
    U.A.E
    Address
    Address
    P.O. Box 997 Airport Road, Digdaga Ras Al Khaimah, United Arab Emirates
    Telephone
    Telephone
    +971 7 246 1461
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.julphar.net/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    BPI Europe

    BPI Europe

    Not Confirmed

    envelop Contact Supplier

    BPI Europe

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Novartis exploring Saudi Arabia for production of cancer drugs
    Novartis exploring Saudi Arabia for production of cancer drugs

    10 May 2019

    // Eric Palmer FIERCE PHARMA

    https://www.fiercepharma.com/manufacturing/novartis-sees-saudi-arabia-as-promising-market-for-producing-its-cancer-drugs

    Eric Palmer FIERCE PHARMA
    10 May 2019
    Share Share
    Julphar Saudi Arabia opens 75,000-square-meter plant in Saudi Arabia
    Julphar Saudi Arabia opens 75,000-square-meter plant in Saudi Arabia

    02 May 2017

    // Eric Palmer FIERCE PHARMA

    http://www.fiercepharma.com/manufacturing/julphar-saudi-arabia-opens-75-000-square-meter-plant-saudi-arabia

    Eric Palmer FIERCE PHARMA
    02 May 2017
    Share Share

    Drugs in Development

    read-more
    read-more
    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Pharmacokinetic (PK) Bioequivalence and Pharmacodynamics (PD) of Julphar Insulin N and Huminsulin® Basal

    Details:

    Insulin is a Hormone drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Diabetes Mellitus.


    Lead Product(s): Insulin

    Therapeutic Area: Endocrinology Brand Name: Undisclosed

    Study Phase: Phase IProduct Type: Hormone

    Sponsor: Profil Institut für Stoffwechselforschung GmbH

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable December 18, 2015

    blank

    01

    Julphar Gulf Pharmaceutical Industries

    U.A.E
    arrow
    Sampe
    Not Confirmed

    Julphar Gulf Pharmaceutical Industries

    U.A.E
    arrow
    Sampe
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Insulin

    Therapeutic Area : Endocrinology

    Highest Development Status : Phase I

    Partner/Sponsor/Collaborator : Profil Institut für Stoffwechselforschung GmbH

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Pharmacokinetic (PK) Bioequivalence and Pharmacodynamics (PD) of Julphar Insulin N and HuminsulinÃ...

    Details : Insulin is a Hormone drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Diabetes Mellitus.

    Product Name : Undisclosed

    Product Type : Hormone

    Upfront Cash : Inapplicable

    December 18, 2015

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Pharmacokinetic (PK) Bioequivalence and Pharmacodynamics of Julphar Insulin R and Huminsulin® Normal

    Details:

    Human Insulin is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Diabetes Mellitus.


    Lead Product(s): Insulin Lispro

    Therapeutic Area: Endocrinology Brand Name: Undisclosed

    Study Phase: Phase IProduct Type: Protein

    Sponsor: Profil Institut für Stoffwechselforschung GmbH | Parexel

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable December 18, 2015

    blank

    02

    Julphar Gulf Pharmaceutical Industries

    U.A.E
    arrow
    Sampe
    Not Confirmed

    Julphar Gulf Pharmaceutical Industries

    U.A.E
    arrow
    Sampe
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Insulin Lispro

    Therapeutic Area : Endocrinology

    Highest Development Status : Phase I

    Partner/Sponsor/Collaborator : Profil Institut für Stoffwechselforschung GmbH | Parexel

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Pharmacokinetic (PK) Bioequivalence and Pharmacodynamics of Julphar Insulin R and Huminsulin® N...

    Details : Human Insulin is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Diabetes Mellitus.

    Product Name : Undisclosed

    Product Type : Protein

    Upfront Cash : Inapplicable

    December 18, 2015

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Pharmacokinetic (PK) Bioequivalence and Pharmacodynamics (PD) of Julphar Insulin 30/70 and Huminsulin® Profil III

    Details:

    Human Biphasic Insulin is a Hormone drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Diabetes Mellitus.


    Lead Product(s): Human Biphasic Insulin

    Therapeutic Area: Endocrinology Brand Name: Undisclosed

    Study Phase: Phase IProduct Type: Hormone

    Sponsor: Profil Institut für Stoffwechselforschung GmbH

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable December 16, 2015

    blank

    03

    Julphar Gulf Pharmaceutical Industries

    U.A.E
    arrow
    Sampe
    Not Confirmed

    Julphar Gulf Pharmaceutical Industries

    U.A.E
    arrow
    Sampe
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Human Biphasic Insulin

    Therapeutic Area : Endocrinology

    Highest Development Status : Phase I

    Partner/Sponsor/Collaborator : Profil Institut für Stoffwechselforschung GmbH

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Pharmacokinetic (PK) Bioequivalence and Pharmacodynamics (PD) of Julphar Insulin 30/70 and Huminsu...

    Details : Human Biphasic Insulin is a Hormone drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Diabetes Mellitus.

    Product Name : Undisclosed

    Product Type : Hormone

    Upfront Cash : Inapplicable

    December 16, 2015

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search